DBV Technologies S.A.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Châtillon, France, with North American operations in Warren, New Jersey. The company's core business is dedicated to advancing epicutaneous immunotherapy (EPIT) through its proprietary VIASKIN® patch technology. Its mission is to develop innovative treatment options for immunological diseases with significant unmet medical needs, primarily focusing on food allergies.

The cornerstone of DBV Technologies' product portfolio is the VIASKIN® patch, designed to deliver biologically active compounds to the immune system through intact skin, aiming to desensitize patients to allergens. The company's lead product candidate, VIASKIN® Peanut, is in late-stage clinical development for the treatment of peanut allergies in children and toddlers, with Biologics License Application (BLA) resubmissions to the U.S. FDA anticipated in 2026. Other pipeline programs include VIASKIN® Milk for cow's milk protein allergy and eosinophilic esophagitis (EoE), as well as exploratory applications for other immunological disorders and vaccines.

Led by CEO Daniel Tassé, DBV Technologies recently reported its first-quarter 2026 financial results, indicating a widened net loss as the company ramps up research and development and commercial preparation for VIASKIN® Peanut. The company's market position is characterized by its innovative approach to immunotherapy and the anticipated commercialization of its lead product, following positive Phase 3 VITESSE trial results for VIASKIN® Peanut in late 2025.